Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vernalis, Endo in Frova deal

Vernalis (LSE:VER; VNLS) granted ENDP exclusive North American sales and marketing rights for migraine drug Frova frovatriptan. ENDP also

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE